Testosterone Cypionate Powder Test C Test Cyp Body Building Steroid Raw Powder CAS 58-20-8

Testosterone Cypionate

Quick Details:

Product name    Testosterone Cypionate
Other name    test cyp
CAS    58-20-8
EINECS    200-368-4
MF    C27H40O3
MW  412.61
Assay 99.8%

Description:

Testosterone cypionate is a slowly injectable lipid form of the male androgen testosterone. Testosterone is also the anabolic hormone in men and is the basis for all other anabolic/androgenic steroids. Like all testosterone injections, testosterone cypionate is favored by athletes for its ability to promote increases in muscle mass and strength. It's worth noting that even though a large number of other steroid compounds are also available as injectables, they are still considered primary fillers for bodybuilders. There is little dispute that testosterone cypionate is one of the most powerful drugs available.

History:
Testosterone cypionate first appeared on the U.S. drug market in the mid-1950s under the brand name Proline Testosterone Cypionyl Propionate (soon to be shortened to Depo-Testosterone). It was developed by pharmaceutical giant Upjohn and is still marketed under the same brand name to the same company (although it is now called Pharmacia & Upjohn). This is a drug with limited global availability that has historically been (mostly) identified as a US drug. Not surprisingly, American athletes have long championed this form of testosterone, the slow-acting ester that dominates the global market. However, this preference may be due to history and availability rather than actual therapeutic advantage.

Testosterone Propionate and Testosterone Enanthate provide very similar testosterone release patterns. It is impossible to notice actual differences in pharmacokinetic profiles in one person (the two drugs are for all intents and purposes functionally interchangeable). The only key difference between the two is patient comfort. In a small proportion of patients, testosterone cypionate was less irritating at the injection site than the control (testosterone enanthate). This makes testosterone cypionate more beneficial for patients who experience pain when injected with testosterone enanthate. This discrepancy may be related to the early development of this testosterone ester as a commercial drug product.

Testosterone cypionate has been used in clinical medicine as a treatment for low androgen levels in men, although the drug is also used for other treatments. For example, in the 1960s, the drug was prescribed to help mature bone structure, treat menorrhagia (menorrhagia), excessive breastfeeding in women, increase muscle mass, and combat osteoporosis in the elderly. It is also recommended for male fertility enhancement, including treatment of testosterone/sperm suppression (caused by administration of 200 mg testosterone per week for 6 to 10 weeks), and rebound sperm production (due to temporarily higher than normal gonadotropin levels).

By the 1970s, the FDA had exerted stronger control over the prescription drug market, and the widespread use of testosterone was narrowed down for the first time. For example, "testosterone rebound therapy" as a way to increase male fertility proved unreliable, especially in the face of newer and more effective drugs, and was quickly eliminated from prescribing guidelines. Recommended for matters such as menorrhagia and lactation. Overall, testosterone therapy is being repurposed to treat androgen deficiency in men and to a lesser extent otherwise, especially when dealing with populations more susceptible to androgenic side effects, such as women and the elderly.

Today, testosterone cypionate is still available on the U.S. prescription drug market and is FDA-approved for male hormone replacement therapy, as well as for conditions associated with endogenous testosterone deficiency, and as adjuvant treatment for inoperable metastatic breast cancer in women (although It is no longer widely used for this purpose). Testosterone cypionate is currently available outside the United States, but not widely. Known international sources of the drug include Canada, Australia, Spain, Brazil and South Africa.

Structural features:

Testosterone cypionate is a modified form of testosterone in which a carboxylate (cyclopentylpropionate) has been attached to the 17-beta hydroxyl group. The esterified form of testosterone is less polar than free testosterone and is absorbed more slowly in the injected area. Once in the blood, the fat is removed to produce free (active) testosterone. Testosterone was designed as an esterified form to prolong the window of therapeutic effect after administration, allowing for a less frequent injection regimen compared to injecting free (non-esterified) steroids. The half-life of cypionate testosterone is about 12 days after injection

Testosterone readily aromatizes in the body to estradiol (estrogen). Aromatase (estrogen synthase) is responsible for the metabolism of testosterone. Elevated estrogen levels can cause side effects such as increased water intake, increased body fat, and gynecomastia. Testosterone is considered a moderately estrogenic steroid. Anti-estrogen, can use aromatase inhibitors, such as anastrozole (anastrozole) to control estrogen more effectively.

Estrogenic side effects will occur in a dose-dependent manner, with higher doses (above normal therapeutic levels) of testosterone more requiring concomitant antiestrogens or aromatase inhibitors. Since loss of water retention and muscle is common with higher doses of Testosterone Propionate, this drug is generally considered a poor choice for dieting or cutting phases. Its moderate estrogenicity makes it more suitable for the bulking phase, and its stored water will provide raw muscle strength and size and help provide a more anabolic environment.

Side Effects :

1.androgenic

Testosterone is the main male androgen responsible for maintaining male secondary sex characteristics. Elevated testosterone levels may produce androgenic side effects. Women are also warned of the potential pathogenic effects of anabolic/androgenic steroids, especially strong androgens such as testosterone, which may include deepening of the voice, menstrual irregularities, changes in skin texture, facial hair growth, and clitoral enlargement.

In androgen-responsive target tissues such as skin, scalp, and prostate, the high relative androgenicity of testosterone is due to its reduction to dihydrotestosterone (DHT). 5-alpha reductase is the main cause of testosterone metabolism. Concomitant use of 5-alpha reductase inhibitors such as finasteride or dutasteride interferes with the site-specificity of testosterone action and reduces the propensity of testosterone drugs to produce androgenic side effects. It is important to remember that both anabolic and androgenic effects are mediated through the androgen receptor. Complete separation of the anabolic and androgenic effects of testosterone is not possible, even with inhibition of all 5-alpha reductases.

2.Hepatotoxicity

Testosterone has no hepatotoxic effects, and one study examined the hepatotoxic potential of high-dose testosterone by administering 400 mg of the hormone daily (2,800 mg per week) to a group of male subjects. After 20 days of steroid administration, there was no significant change in liver enzyme values, including serum albumin, bilirubin, alanine-aminotransferase, and alkaline phosphatase.

3.Cardiovascular

Anabolic/androgenic steroids can have deleterious effects on serum cholesterol. This includes a tendency to lower HDL (good) cholesterol levels and increase LDL (bad) cholesterol levels, and possibly convert HDL to LDL, leading to a greater risk of arteriosclerosis. The relative effects of anabolic/androgenic steroids on serum lipids depend on dose, route of administration (oral vs parenteral), type of steroid (aromatizable or non-aromatizable), and level of resistance to hepatic metabolism. Anabolic/androgenic steroids may also adversely affect blood pressure and triglycerides, reduce endothelial relaxation, and cause left ventricular hypertrophy.

Compared with anabolic steroids, testosterone has a much smaller effect on cardiovascular risk factors. Partly because of its openness to hepatic metabolism, it has less impact on the hepatic management of cholesterol. Aromatization of testosterone with estradiol also helps to attenuate the negative effects of androgens on serum lipids. In one study, 280 mg of testosterone ester (enanthate) per week had a slight but not statistically significant effect on HDL cholesterol after 12 weeks, but a strong (25%) effect was observed when an aromatase inhibitor was taken decrease. Using 300 mg of testosterone ester (enanthate) weekly for 20 weeks without an aromatase inhibitor showed only a 13% reduction in HDL cholesterol, while at 600 mg, the reduction reached 21%. Negative effects of aromatase inhibition should be considered prior to testosterone therapy.

Tamoxifen citrate or clomiphene citrate are preferred over aromatase inhibitors because of the positive effects of estrogen on serum lipids and because they have partial estrogenic effects in the liver. This allows them to potentially improve lipid profile and counteract some of the negative effects of androgens. At doses of 600 mg weekly or less, the effect on the lipid profile tends to be pronounced but not dramatic, making antiestrogens (for cardioprotective purposes) perhaps unnecessary. Doses of 600 mg or less per week also failed to produce statistically significant changes in LDL/VLDL cholesterol, triglycerides, apolipoprotein B/C-III, C-reactive protein, and insulin sensitivity, suggesting their impact on The influence of cardiovascular risk factors was relatively weak. Injectable testosterone esters are generally considered the safest of all anabolic/androgenic steroids when used in moderate doses.

To help reduce cardiovascular tension, fish oil supplementation (4 grams per day) and a natural cholesterol/antioxidant formula such as Lipid Stabil or a product with similar ingredients are recommended.